Effects of Asymmetric Dimethylarginine on Renal Arteries in Portal Hypertension and Cirrhosis

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2017 Jan 14

PMID 28082806

Citations 3

Authors

Gloria Segarra

Belen Cortina

Maria Dolores Mauricio

Susana Novella

Paloma Lluch

Javier Navarrete-Navarro

Inmaculada Noguera

Pascual Medina

Affiliations

Soon will be listed here.

Abstract

Aim: To evaluate the effects of asymmetric dimethylarginine (ADMA) in renal arteries from portal hypertensive and cirrhotic rats.

Methods: Rat renal arteries from Sham ( = 15), pre-hepatic portal hypertension (PPVL; = 15) and bile duct ligation and excision-induced cirrhosis (BDL; = 15) were precontracted with norepinephrine, and additional contractions were induced with ADMA (10-10 mol/L), an endogenous inhibitor of nitric oxide (NO) synthase. Concentration-response curves to acetylcholine (1 × 10-3 × 10 mol/L) were determined in precontracted renal artery segments with norepinephrine in the absence and in the presence of ADMA. Kidneys were collected to determine the protein expression and activity of dimethylarginine dimethylaminohydrolase (DDAH), an enzyme that catabolizes ADMA.

Results: In renal arteries precontracted with norepinephrine, ADMA caused endothelium-dependent contractions. The pD values to ADMA were similar in the Sham and PPVL groups (4.20 ± 0.08 and 4.11 ± 0.09, > 0.05, respectively), but were lower than those of the BDL group (4.79 ± 0.16, < 0.05). Acetylcholine-induced endothelium-dependent relaxation that did not differ, in terms of pD and maximal relaxation, among the 3 groups studied. Treatment with ADMA (3 × 10 mol/L) inhibited acetylcholine-induced relaxation in the 3 groups, but the inhibition was higher ( < 0.05) in the BDL group compared with that for the Sham and PPVL groups. The mRNA and protein expression of DDAH-1 were similar in kidneys from the three groups. Conversely, DDAH-2 expression was increased ( < 0.05) in PPVL and further enhanced ( < 0.05) in the BDL group. However, renal DDAH activity was significantly decreased in the BDL group.

Conclusion: Cirrhosis increased the inhibitory effect of ADMA on basal- and induced-release of NO in renal arteries, and decreased DDAH activity in the kidney.

Citing Articles

Monocytes subsets altered distribution and dysregulated plasma hsa-miR-21-5p and hsa-miR-155-5p in HCV-linked liver cirrhosis progression to hepatocellular carcinoma.

Hammad R, Eldosoky M, Elmadbouly A, Aglan R, Abdelhamid S, Zaky S J Cancer Res Clin Oncol. 2023; 149(17):15349-15364.

PMID: 37639012 PMC: 10620275. DOI: 10.1007/s00432-023-05313-w.

Glucose 6-P Dehydrogenase Overexpression Improves Aging-Induced Endothelial Dysfunction in Aorta from Mice: Role of Arginase II.

Serna E, Mauricio M, San-Miguel T, Guerra-Ojeda S, Verdu D, Valls A Int J Mol Sci. 2023; 24(4).

PMID: 36835034 PMC: 9961129. DOI: 10.3390/ijms24043622.

DDAH-1, via regulation of ADMA levels, protects against ischemia-induced blood-brain barrier leakage.

Zhao Y, Ma X, Zhou Y, Xie J, Liu X, Zhao Y Lab Invest. 2021; 101(7):808-823.

PMID: 33574439 DOI: 10.1038/s41374-021-00541-5.

References

Tojo A, Welch W, Bremer V, Kimoto M, Kimura K, Omata M . Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int. 1998; 52(6):1593-601. DOI: 10.1038/ki.1997.490. View

Gines P, Guevara M, Arroyo V, Rodes J . Hepatorenal syndrome. Lancet. 2003; 362(9398):1819-27. DOI: 10.1016/S0140-6736(03)14903-3. View

Lluch P, Mauricio M, Vila J, Segarra G, Medina P, del Olmo J . Accumulation of symmetric dimethylarginine in hepatorenal syndrome. Exp Biol Med (Maywood). 2005; 231(1):70-5. DOI: 10.1177/153537020623100108. View

Kielstein J, Boger R, Bode-Boger S, Schaffer J, Barbey M, Koch K . Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol. 1999; 10(3):594-600. DOI: 10.1681/ASN.V103594. View

MacAllister R, Parry H, Kimoto M, Ogawa T, Russell R, Hodson H . Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol. 1996; 119(8):1533-40. PMC: 1915783. DOI: 10.1111/j.1476-5381.1996.tb16069.x. View

Lluch P, Torondel B, Medina P, Segarra G, del Olmo J, Serra M . Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. J Hepatol. 2004; 41(1):55-9. DOI: 10.1016/j.jhep.2004.03.016. View

Vallance P, Collier J, Moncada S . Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 1989; 2(8670):997-1000. DOI: 10.1016/s0140-6736(89)91013-1. View

Jacobi J, Sydow K, von Degenfeld G, Zhang Y, Dayoub H, Wang B . Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation. 2005; 111(11):1431-8. DOI: 10.1161/01.CIR.0000158487.80483.09. View

Nijveldt R, Teerlink T, van Leeuwen P . The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis. Clin Nutr. 2003; 22(1):99-104. DOI: 10.1054/clnu.2002.0614. View

10.

Sieber C, Lopez-Talavera J, Groszmann R . Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. Gastroenterology. 1993; 104(6):1750-4. DOI: 10.1016/0016-5085(93)90655-v. View

11.

Bachmann S, Mundel P . Nitric oxide in the kidney: synthesis, localization, and function. Am J Kidney Dis. 1994; 24(1):112-29. DOI: 10.1016/s0272-6386(12)80170-3. View

12.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

13.

Mookerjee R, Mehta G, Balasubramaniyan V, Mohamed F, Davies N, Sharma V . Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension. J Hepatol. 2014; 62(2):325-31. PMC: 4530584. DOI: 10.1016/j.jhep.2014.08.024. View

14.

Kimoto M, Tsuji H, Ogawa T, Sasaoka K . Detection of NG,NG-dimethylarginine dimethylaminohydrolase in the nitric oxide-generating systems of rats using monoclonal antibody. Arch Biochem Biophys. 1993; 300(2):657-62. DOI: 10.1006/abbi.1993.1091. View

15.

Leiper J, Santa Maria J, Chubb A, MacAllister R, Charles I, Whitley G . Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J. 1999; 343 Pt 1:209-14. PMC: 1220543. View

16.

Serna E, Mauricio M, Lluch P, Segarra G, Cortina B, Lluch S . Basal release of nitric oxide in the mesenteric artery in portal hypertension and cirrhosis: role of dimethylarginine dimethylaminohydrolase. J Gastroenterol Hepatol. 2013; 28(5):880-6. DOI: 10.1111/jgh.12119. View

17.

Segarra G, Medina P, Ballester R, Lluch P, Aldasoro M, Vila J . Effects of some guanidino compounds on human cerebral arteries. Stroke. 1999; 30(10):2206-10; discussion 2210-11. DOI: 10.1161/01.str.30.10.2206. View

18.

Vallance P, Leone A, Calver A, Collier J, Moncada S . Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol. 1992; 20 Suppl 12:S60-2. DOI: 10.1097/00005344-199204002-00018. View

19.

Lluch P, Segarra G, Medina P . Asymmetric dimethylarginine as a mediator of vascular dysfunction in cirrhosis. World J Gastroenterol. 2015; 21(32):9466-75. PMC: 4548108. DOI: 10.3748/wjg.v21.i32.9466. View

20.

Hennenberg M, Trebicka J, Biecker E, Schepke M, Sauerbruch T, Heller J . Vascular dysfunction in human and rat cirrhosis: role of receptor-desensitizing and calcium-sensitizing proteins. Hepatology. 2007; 45(2):495-506. DOI: 10.1002/hep.21502. View